Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10575962 | 0.88 | SIGMAR1 (0.54) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10575967 | 0.80 | SIGMAR1 (0.63) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL16349422 | 0.73 | SIGMAR1 (0.45) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL30751975 | 0.73 | SIGMAR1 (0.55) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10578986 | 0.73 | SMN1; SMN2 (0.41) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL10578990 | 0.73 | SMN1; SMN2 (0.41) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL24726743 | 0.71 | SMN1; SMN2 (0.46) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL19240804 | 0.71 | SMN1; SMN2 (0.46) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL19486631 | 0.71 | SMN1; SMN2 (0.46) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL11729576 | 0.71 | SMN1; SMN2 (0.46) | SIGMAR1SMN1; SMN2NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | VYMED CORPORATION (US) | 2014-03-13 | — | — | US | disclosed |
| EP-1406619-A4 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | SHETTY B VITHAL (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040132993-A1 | Antiviral and antimicrobial guanidine or biguanidine derivatives | SHETTY B VITHAL (US) | 2004-07-08 | — | — | US | disclosed |
| EP-1406619-A1 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | Shetty, B. Vithal (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6699989-B1 | HUMAN T-CELL LEUKEMIA/LYMPHOMA VIRUS (HTLV) AND LYMPHADENOPATHY ASSOCIATED VIRUS TREATMENT; AIDS | VYMED CORPORATION | 2004-03-02 | — | — | US | disclosed |
| WO-2002017916-A1 | ANTIVIRAL AND ANTIMICROBIAL GUANIDINE OR BIGUANIDINE DERIVATIVES | SHETTY B VITHAL (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073631-A1 | ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS | GDA, GMPS, GANC | SIGMAR1 1306/4885SMN1; SMN2 2638/4885NPC1 1606/4885 |
| US-20040132993-A1 | Antiviral and antimicrobial guanidine or biguanidine derivatives | GMPS, GDA, GANC | SIGMAR1 1326/4885SMN1; SMN2 3387/4885NPC1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.